Royalty Pharma PLC $RPRX Stock Purchased by Vise Technologies Inc.

Vise Technologies Inc. raised its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 35.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,473 shares of the biopharmaceutical company’s stock after acquiring an additional 8,515 shares during the quarter. Vise Technologies Inc.’s holdings in Royalty Pharma were worth $1,895,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bank of America Corp DE raised its stake in Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock worth $167,696,000 after acquiring an additional 786,921 shares in the last quarter. Amundi boosted its stake in shares of Royalty Pharma by 15.3% in the 1st quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company’s stock valued at $148,168,000 after purchasing an additional 409,394 shares in the last quarter. Dorsey Asset Management LLC boosted its stake in shares of Royalty Pharma by 0.8% in the 1st quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock valued at $109,207,000 after purchasing an additional 17,101 shares in the last quarter. Hsbc Holdings PLC boosted its stake in shares of Royalty Pharma by 2,562.2% in the 1st quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company’s stock valued at $74,000,000 after purchasing an additional 1,486,020 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its holdings in shares of Royalty Pharma by 28.2% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 1,168,427 shares of the biopharmaceutical company’s stock valued at $68,189,000 after purchasing an additional 256,841 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $67.57 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. The firm has a 50-day moving average of $60.71 and a 200-day moving average of $53.67. Royalty Pharma PLC has a one year low of $37.31 and a one year high of $69.77. The company has a market cap of $38.85 billion, a P/E ratio of 56.31, a P/E/G ratio of 1.85 and a beta of 0.37.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.05. Royalty Pharma had a net margin of 25.68% and a return on equity of 30.02%. The company had revenue of $674.14 million during the quarter, compared to analyst estimates of $758.93 million. Equities research analysts forecast that Royalty Pharma PLC will post 5.29 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $0.2350 per share. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. Royalty Pharma’s dividend payout ratio is presently 78.33%.

Insider Buying and Selling at Royalty Pharma

In related news, EVP Marshall Urist sold 4,126 shares of Royalty Pharma stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the sale, the executive vice president owned 270,401 shares in the company, valued at $15,826,570.53. This represents a 27.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 208,252 shares of company stock valued at $12,324,407 in the last quarter. 18.84% of the stock is owned by corporate insiders.

Key Stories Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Citigroup raised its price target to $78 from $70 and reiterated a Buy rating, citing potential upside from the current share price. TickerReport article
• Positive Sentiment: Royalty Pharma raised its 2026 royalty-receipts outlook to $3.55 billion. The improved forecast may support expectations for continued business growth. RTTNews article
• Positive Sentiment: On an adjusted basis, third-quarter EPS was reported at $1.21, ahead of the $1.18 consensus estimate and up from $1.17 a year earlier. Zacks also reported revenue above its estimate. Zacks article
• Neutral Sentiment: Published earnings summaries show different figures for EPS and revenue, reflecting differing measures or estimates. Investors should distinguish adjusted results from GAAP results when assessing the quarter. Business Insider results
• Negative Sentiment: One report put GAAP EPS at $0.32, below the $1.18 consensus, and revenue at $690.1 million versus an $884.8 million estimate. That reported shortfall could temper optimism about the adjusted earnings beat. MarketBeat earnings report

Wall Street Analyst Weigh In

RPRX has been the topic of several recent analyst reports. Morgan Stanley boosted their price target on Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Citigroup raised their price objective on shares of Royalty Pharma from $70.00 to $78.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 26th. Eight investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $63.29.

Royalty Pharma Company Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.